Found in Translation

Under his IDH2: Epigenetic drivers of clonal hematopoiesis


 

Dr. Viny is with the Memorial Sloan-Kettering Cancer Center, N.Y., where he is a clinical instructor, is on the staff of the leukemia service, and is a clinical researcher in the Ross Levine Lab.

References

1. Orkin SH and Zon L. Cell. 2008 Feb 22;132(4):631-44.

2. Jongen-Lavrencic M et al. N Engl J Med 2018; 378:1189-99.

3. Bhatnagar B et al. Br J Haematol. 2016 Oct;175(2):226-36.

4. Shlush LI et al. Nature. 2017;547:104-8.

5. Bowman RL et al. Cell Stem Cell. 2018 Feb 1;22(2):157-70.

Pages

Recommended Reading

Improving survival in older AML patients
MDedge Hematology and Oncology
FDA to review FLT3 agent for refractory AML
MDedge Hematology and Oncology
FDA grants priority review to gilteritinib for R/R AML
MDedge Hematology and Oncology
Protein may be therapeutic target for AML
MDedge Hematology and Oncology
NCCN releases guidelines for AML patients
MDedge Hematology and Oncology
CAR T-cell therapy bridges to HSCT in AML patient
MDedge Hematology and Oncology
Y chromosome gene protects against AML
MDedge Hematology and Oncology
Potential therapeutic target for type of AML
MDedge Hematology and Oncology
GO approved to treat AML in Europe
MDedge Hematology and Oncology
Art education benefits blood cancer patients
MDedge Hematology and Oncology